WASHINGTON — Ted Love has pretty much done everything there is to do in biotech.
He’s worked for tiny startups and mega corporations. He sold his latest company to Pfizer for $5 billion amid an industry downturn. And now, he’s taking on a new challenge by becoming the chair of the board of the largest biotechnology lobby, BIO.
He hopes to use his experience across the drug development process to improve the biotech industry’s reputation in Washington, following a bruising lobbying fight the industry lost when Democrats gave Medicare the power to negotiate drug prices, and the organization’s messy separation from its former CEO last year.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.